Earnings Release • Mar 26, 2015
Earnings Release
Open in ViewerOpens in native device viewer
Louvain-La-Neuve, Belgium, 26 March 2015 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated annual results for the 2014 financial year.
| 2014 (EUR 000) |
2013 (EUR 000) |
Variance (EUR 000) |
Variance % |
|
|---|---|---|---|---|
| Proton Therapy & Other Accelerators |
177 687 |
166 589 |
11 098 |
6.7% |
| Dosimetry | 42 890 |
45 923 |
-3 033 | -6.6% |
| Total Net Sales | 220 577 |
212 512 |
8 065 |
3.8% |
| REBITDA | 28 321 |
22 743 |
5 578 |
24.5% |
| % of Sales | 12.8% | 10.7% | ||
| REBIT | 22 932 |
18 359 |
4 573 |
24.9% |
| % of Sales | 10.4% | 8.6% | ||
| Profit Before Tax | 17 173 |
-408 | 17 581 |
N/A |
| % of Sales | 7.8% | -0.2% | ||
| NET RESULT | 24 294 |
-1 011 |
25 305 |
N/A |
| % of Sales | 11.0% | -0.5% |
REBITDA: Recurring earnings before interest, taxes, depreciation and amortization REBIT: Recurring earnings before interest and taxes
Press release | 26 March 2015 1 | 11
Regulated information
Strategic global collaboration signed with Philips Healthcare in sales, marketing and research and development (R&D) for imaging and therapy solutions in oncology
Olivier Legrain, Chief Executive Officer of IBA, commented: "2014 was a transformational year for IBA that saw the Company benefit from increasing global adoption and acceptance of proton therapy as the most advanced and precise treatment option for radiation therapy patients. IBA has continued to maintain its strong leadership in the field, securing more than 50% of all proton therapy orders in 2014. Our investments in proton therapy developments, such as Proteus®ONE, precision delivery in Pencil Beam Scanning and imaging in CBCT are key differentiators for our customers. IBA remains at the forefront of technological advances in radiation therapy and is increasingly seeking to enhance its position in new innovations such as adaptive and carbon therapy.
"Asia and the emerging markets are increasingly strong markets for IBA, with four of our system sales coming from that region in 2014. IBA started 2015 with a strong order book, a record backlog and a very healthy pipeline. With sales and interest in our proton therapy systems growing globally and the increasing affordability and availability of finance for these systems, we are confident of continuing our strong progress in the coming year and beyond."
Regulated information
This conference call will be held on 26 March 2015 at 15:00 CET / 14:00 GMT / 10:00 EDT and can be accessed online at: http://arkadinemea-events.adobeconnect.com/iba. If you would like to participate in the Q&A, please dial (PIN code 26496158#):
| +32 2 404 03 05 |
|---|
| +44 20 7750 9926 |
| +31 20 713 34 88 |
| +352 2786 01 66 |
| +1 914 885 07 79 |
| +33 1 72 04 00 33 |
The presentation will be available on the IBA website shortly after the call.
General Assembly 2015 May 13, 2015 First quarter business update May 13, 2015 Half Year results August 27, 2015 Third quarter business update November 17, 2015
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
* Proteus®ONE is the brand name of a new configuration of the Proteus® 235.
Jean-Marc Bothy Chief Financial Officer Tel: +32 10 47 58 90
Thomas Ralet Vice-President Corporate Communication +32 10 47 58 90 [email protected]
Consilium Strategic Communications Amber Bielecka, Matthew Neal, Ivar Milligan, Jessica Hodgson +44 (0)20 3709 5700 [email protected]
Rx Communications Group (US) Melody Carey + 1 917 322 2571 [email protected]
Press release | 26 March 2015 3 | 11
Regulated information
| FY 2014 (EUR 000) |
FY 2013 (EUR 000) |
Variance (EUR 000) |
Variance % |
|
|---|---|---|---|---|
| Net Sales | 177 687 | 166 589 | 11 098 | 6.7% |
| - Proton Therapy |
128 488 | 121 202 | 7 286 | 6.0% |
| - Other Accelerators |
49 199 | 45 387 | 3 812 | 8.4% |
| REBITDA | 24 148 | 15 320 | 8 828 | 57.6% |
| % of Sales | 13.6% | 9.2% | ||
| REBIT | 19 516 | 11 644 | 7 872 | 67.6% |
| % of Sales | 11.0% | 7.0% |
Net sales grew by 6.7% in 2014 for Proton Therapy and Other Accelerators, driven in part by continued strong growth of sustainable service revenues, making up about one third of the total.
Proton Therapy service revenues alone increased by 42.8% and, including Other Accelerators, by 32.4%, further indicating the sustainability and predictability of this important revenue stream. The Company now has 27 PT service contracts signed, totalling a backlog of EUR 468 million in future booked revenues over the next 10-15 years.
In addition, IBA has a record year-end backlog in Proton Therapy and Other Accelerators of EUR 256.2 million, up 39% from EUR 183.8 million at the end of 2013.
2014 was a transformational year for proton therapy in which the sector has seen significant market growth. IBA sees this as being driven by three factors: Clinical Relevance, a growing body of clinical publications is propelling greater use of proton therapy. Additionally, ASTRO (the American Society for Radiation Oncology), has now published Model Policies for Proton Beam Therapy, guiding its use in the important US market. Affordability, our compact system Proteus®ONE, which came into clinical use in 2014, is opening the single room market to IBA due to its smaller footprint and shorter installation time. With no compromise on clinical quality, IBA is focused on reducing the delta between the cost of proton therapy and conventional radiation therapy.
Enhancements in Technology, have also been key for IBA in 2014. Significant improvements in fast pencil beam scanning (PBS) and Cone Beam Computed Tomography (CBCT). Moreover, IBA has remained at the forefront of proton therapy technology evolution and is also enhancing its position in the treatment modalities of the future with developments in carbon therapy. Carbon ions have similar physical characteristics to protons, but have a greater Radio Biological Effectiveness (RBE) making them more efficient on radiation-resistant tumors.
Throughout 2014, IBA saw a growing market interest in Proteus®ONE and sold four Proteus®ONE systems including two in Japan, one in the US and one in France. IBA now has orders for seven systems globally in Japan (2), France (2), US (2) and Taiwan (1). 2014 was also a strong year for the Company's multi-room system, Proteus®PLUS, with two sales (six rooms) in China, bringing the total number sold globally to 24 units (80 rooms).
Regulated information
In The Netherlands, IBA was selected for the installation of a Proteus®PLUS two-gantry room configuration including its next generation Pencil Beam Scanning capability at the Universitair Medisch Centrum Groningen (UMCG) proton therapy center, the first to be built in the country and worth approximately EUR 50 million to IBA, including a long-term operations and maintenance contract.
Demonstrating increasing strength in Asia, and in addition to the two Proteus®ONE systems sold in Japan, IBA was selected by Guangdong Hengju Medical Technologies Co. Ltd, to install its Proteus®PLUS system with PBS capability in Guangzhou, South China. Moreover, in January 2015, IBA also announced it had signed a contract at the end of 2014 with the Zhuozhou Jian Kang Qiao Investment Company Ltd, to establish a proton therapy center in Zhuozhou City, Hebei Province, China. This contract is worth more than EUR 80 million to IBA, including the service contract.
The speed at which IBA can build its systems, and the time in which it can enable its customers to treat patients is continuously decreasing, are critical factors in a customer's decision making process when choosing a provider.
IBA is at the forefront of advancing proton therapy technology and, during 2014, the Company received Marketing Authorization from the US Food and Drug Administration (FDA) and CE marking for the Compact Gantry Beam Line. IBA also received the FDA approval and CE mark for the CBCT solution, which improves the precision in IBA's proton therapy systems. CBCT enables highly accurate patient positioning. Specific applications of image guidance and image monitoring are key factors in delivering superior dose distribution of proton therapy. By adding CBCT as one of IBA's Image Guided Proton Therapy solutions, IBA is leading the development of adaptive proton therapy.
IBA has sought to further enhance its own in-house technological advances with collaborations with some of the world's leading academic institutions and companies. For example, IBA is working closely with Penn Medicine to develop new PBS protocols as well as combining forces with Philips Healthcare (Philips) through a strategic global collaboration to provide advanced diagnostic and therapeutic solutions for the treatment of cancer. The collaboration covers sales, marketing and R&D of imaging and therapy solutions in oncology. IBA will benefit from Philips' diagnostic imaging products offered to oncology care centers, while Philips will leverage IBA's proton therapy solutions within its offering for customers in select markets around the world.
IBA is also using collaborations to advance its capabilities in next generation radiation therapy capabilities. As part of its work with CYCLHAD (a CYCLotron for HADron Therapy) for the installation of its single-room proton therapy system Proteus®ONE in Caen, France, IBA will also work with several French industrial partners and semi-public institutions to develop the potential of carbon beam therapy.
IBA's Other Accelerators division delivered strong growth during 2014, again with significant gains seen in emerging markets. Revenues rose 8.4% to EUR 49.2 million, from EUR 45.4 million in 2013.
2014 was another record year of cyclotron sales for IBA's RadioPharma Solutions division, with important contracts won in all key regions. For example, in July 2014, IBA signed its third Cyclone® 70 contract in Russia, a system dedicated to the production of new-generation medical isotopes used mainly in the diagnosis of severe diseases. This third Cyclone® 70 order further demonstrates IBA's
Regulated information
market-leading expertise and success with cyclotron sales. 2014 was also a record sales year for Synthera® , IBA's automated chemistry module for the production of radiopharmaceuticals.
IBA's Industrial Accelerators division supplies electron beams and focuses on two markets: the sterilization of single-use medical products and the improvement of the physical properties of polymers (crosslinking). IBA Industrial Accelerators is the market leader, with more than 50% market share in average over the last five years. Growth in the polymer crosslinking market mainly comes from the automotive industry, where manufacturers require cables treated by electron beams that are both more compact and offer superior performance.
In 2014, IBA delivered its first Rhodotron® with progressive power design allowing customers to start with small capacity solutions and increase capacity when needed. IBA also sold the first Rhodotron® DUO, a new configuration that allows its customers to sterilize medical devices either by X-ray or by electron beam treatment. This new solution allows the industry to break the dependence on chemical or radioactive based competing sterilization processes.
IBA Industrial is evaluating new long term markets such as container screening and energy saving solutions. Those new markets could contribute to growth of the segment.
| FY 2014 (EUR 000) |
FY 2013 (EUR 000) |
Variance (EUR 000) |
Variance % |
|
|---|---|---|---|---|
| Net Sales | 42 890 | 45 923 | -3 033 |
-6.6% |
| - Dosimetry |
42 890 | 45 923 | -3 033 | |
| REBITDA | 4 173 | 7 423 | -3 250 | -43.8% |
| % of Sales | 9.7% | 16.2% | ||
| REBIT | 3 417 | 6 715 | -3 298 | -49.1% |
| % of Sales | 8.0% | 14.6% |
In Dosimetry, IBA has been facing the same phenomenon reported by the main players in the linear accelerators (LINAC) market, with strong order intake in the emerging countries from multi-year orders that take longer to be converted into revenues than with previous established market contracts. Therefore, the strong order intake, unexpectedly, only converted into a limited amount of revenues causing a decrease in sales to EUR 42.89 million and REBIT of EUR 3.41 million.
However, with a strong backlog of EUR 16.8 million, up 39% compared to full year 2013, increasing synergies between dosimetry and proton therapy, stabilization of the conversion rate and new, innovative product solutions and services introduced in 2014, IBA is confident that Dosimetry will return to growth in 2015.
IBA Dosimetry has been fully focused on enhancing innovation in its solutions and services to remain the go-to provider of high quality dosimetry technologies.
In addition, IBA Dosimetry introduced several new integrated solutions for patient safety in 2014, including a unique software platform for quality assurance called myQA® and the next evolution in patient safety, Dolphin® .
Regulated information
Dolphin® provides online care and enables a less stressful and safer treatment experience for patients. The QuickCheck™ software automatically analyzes the delivered fraction versus the dose defined in the treatment plan and automatically confirms its accuracy after each fraction. Dolphin® provides online confidence that the entire treatment has been delivered safely, fraction by fraction.
IBA reported a 3.8% increase in revenues to EUR 220.6 million during 2014 (2013: EUR 212.5 million).
Recurring operating profits before interest and taxes (REBIT) continued to improve compared with 2013, due to the growth in service revenues (+28%) and benefits from the implementation of the Company's productivity and efficiency programme. The Company's REBIT increased 24.9% in 2014 from EUR 18.4 million in 2013 to EUR 22.9 million in 2014 despite the low level of revenue conversion in Dosimetry.
The Board of Directors intends to recommend to the General Assembly that a gross dividend of EUR 0.17 per share be paid in 2015, based on 2014 results, representing a payout ratio of about 20%.
Operating cash flow during 2014 amounted to EUR 15.0 million. Cash flow from investing was positive at EUR 1.7 million.
The net cash position at the year-end was EUR 5.3 million, significantly improved from a net debt EUR 18.1 million at year-end 2013.
Proton therapy's penetration of the radiation therapy market is growing due to increasing clinical relevance, affordability and technological advances. IBA has a record backlog of EUR 256.2 million and the sustainable revenue source from service and maintenance contracts now represents EUR 468 million of revenue over the next 10-15 years. From 2015 to 2018, IBA expects to achieve average revenue growth greater than 10% per annum.
The Company expects its operating margin to stabilize at 10% in 2015 and then grow at 1% per annum until 2018. Net debt is expected to stay limited over the course of the years to come. Due to the necessary continued investments in technological advances in proton therapy to maintain leadership in the space, IBA is planning a dividend payout ratio of 20% in 2015 based on 2014 results, but it is the Company's intention that if market conditions prevail, the dividend should gradually reach a payout ratio of 30% in the future.
Regulated information
The auditor has issued an unqualified audit report on the annual consolidated accounts for the year ended 31 December 2014 and has confirmed that the accounting information included in the press release does not show inconsistencies with the annual consolidated accounts
Diegem, 26 March 2015
Ernst & Young Reviseurs d'Entreprises SCCRL Commissaire Represented by Martine Blockx, Partner
In accordance with the Royal Decree of November 14, 2007, IBA indicates that this announcement was prepared by the Chief Executive Officer (CEO), Olivier Legrain, and the Chief Financial Officer (CFO), Jean-Marc Bothy.
Regulated information
| $34149149$ | |
|---|---|
| 31/12/14 | 31/12/13 | ||
|---|---|---|---|
| (EUR '000) | (EUR '000) | (EUR '000) |
|
| ASSETS | |||
| Goodwill | 3 821 | 3 821 | 0 |
| Other intangible assets | 9 178 | 9 065 | 113 |
| Property, plant and equipment | 8 663 | 7 656 | 1 007 |
| Intercompany investment | 0 | 0 | 0 |
| Investments accounted for using the equity method and other investments | 37 479 | 36 222 | 1 257 |
| Deferred tax assets | 23 018 | 18 044 | 4 974 |
| Long-term financial assets | 1 | 207 | -206 |
| Other long-term assets | 20 539 | 18 291 | 2 248 |
| Non-current assets | 102 699 | 93 306 | 9 393 |
| Inventories and contracts in progress | 91 731 | 72 742 | 18 989 |
| Trade receivables | 54 799 | 41 452 | 13 347 |
| Other receivables | 20 270 | 41 711 | -21 441 |
| Short-term financial assets | 381 | 367 | 14 |
| Assets Held for sale | 0 | 3 233 | -3 233 |
| Cash and cash equivalents | 37 176 | 28 942 | 8 234 |
| Current assets | 204 357 | 188 447 | 15 910 |
| Total assets | 307 056 | 281 753 | 25 303 |
| EQUITY AND LIABILITIES Capital stock |
39 852 | 38 787 | 1 065 |
| Capital surplus | 32 431 | 25 651 | 6 780 |
| Treasury shares | -8 612 | -8 612 | 0 |
| Reserves | 20 786 | 13 339 | 7 447 |
| Currency translation difference | -3 725 | -4 716 | 991 |
| Retained earnings | 26 794 | 2 789 | 24 005 |
| Reserves for assets held for sale | 0 | 0 | 0 |
| Capital and reserves attributable to Company's equity holders | 107 526 | 67 238 | 40 288 |
| Non-controlling interests | 0 | 0 | 0 |
| TOTAL EQUITY | 107 526 | 67 238 | 40 288 |
| Long-term borrowings | 26 679 | 41 871 | -15 192 |
| Long-term financial liabilities | 882 | 553 | 329 |
| Deferred tax liabilities | 854 | 711 | 143 |
| Long-term provisions | 9 607 | 9 649 | -42 |
| Other long-term liabilities | 3 066 | 248 | 2 818 |
| Non-current liabilities | 41 088 | 53 032 | -11 944 |
| Short-term provisions | 7 160 | 21 186 | -14 026 |
| Short-term borrowings | 5 196 | 5 201 | -5 |
| Short-term financial liabilities | 1 759 | 1 027 | 732 |
| Trade payables | 36 145 | 30 819 | 5 326 |
| Current income tax liabilities | 186 | 281 | -95 |
| Other payables | 107 996 | 102 628 | 5 368 |
| Liabilities directly related to assets held for sale | 0 | 341 | -341 |
| Current liabilities | 158 442 | 161 483 | -3 041 |
| Total liabilities | 199 530 | 214 515 | -14 985 |
| Total equity and liabilities | 307 056 | 281 753 | 25 303 |
Press release | 26 March 2015 9 | 11
IBA sa. | Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | Tel.: + 32 10 47 58 11 | Fax: + 32 10 47 58 10 | E-mail: [email protected] | www.iba-worldwide.com | RPM Nivelles | VAT: BE 0428.750.985
Regulated information
| 31/12/14 | 31/12/13 | Variance | ||
|---|---|---|---|---|
| (EUR '000) | (EUR '000) | (EUR '000) | % | |
| Sales and services | 220 577 | 212 512 | 8 065 | 3.8% |
| Cost of sales and services | 124 481 | 124 085 | 396 | 0.3% |
| Gross profit/(loss) | 96 096 | 88 427 | 7 669 | 8.7% |
| 43.6% | 41.6% | |||
| Selling and marketing expenses | 20 111 | 18 322 | 1 790 | 9.8% |
| General and administrative expenses | 30 140 | 28 700 | 1 440 | 5.0% |
| Research and development expenses | 22 912 | 23 046 | -134 | -0.6% |
| Recurring expenses | 73 164 | 70 068 | 3 096 | 4.4% |
| Recurring profit/(loss) | 22 932 | 18 359 | 4 573 | 24.9% |
| 10.4% | 8.6% | |||
| Other operating expenses | 1 973 | 18 739 | -16 766 | -89.5% |
| Other operating (income) | -1 263 | -900 | -363 | 40.3% |
| Financial expenses | 5 318 | 5 105 | 213 | 4.2% |
| Financial (income) | -7 141 | -7 403 | 262 | -3.5% |
| Share of (profit)/loss of equity-accounted companies | 6 873 | 3 226 | 3 647 | 113.0% |
| Profit/(loss) before tax | 17 173 | -408 | 17 580 | N/A |
| Tax (income)/ expenses | -3 413 | -3 384 | -30 | 0.9% |
| Profit/ (loss) for the period from continuing operations | 20 586 | 2 976 | 17 610 | 591.8% |
| Profit/(loss) for the period from discontinued operations | 3 708 | 3 088 | 620 | 20.1% |
| Profit/ (loss) for the period | 24 294 | 6 064 | 18 231 | 300.7% |
| Impact IAS 21.48 | 0 | 7 074 | ||
| Minority interests | 0 | 0 | ||
| Profit/(loss) for the period | 24 294 | -1 011 | 25 305 | N/A |
| REBITDA | 28 321 | 22 743 | 5 578 | 24.5% |
Press release | 26 March 2015 10 | 11
IBA sa. | Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | Tel.: + 32 10 47 58 11 | Fax: + 32 10 47 58 10 | E-mail: [email protected] | www.iba-worldwide.com | RPM Nivelles | VAT: BE 0428.750.985
Regulated information
| (EUR '000) | (EUR | |
|---|---|---|
| Cash flow from operating activities | '000) | |
| Profit/(loss) for the period before technical recycling of CTA | 24 294 | 6 064 |
| Technical recycling of CTA to income statement further to liquidation of a dormant Swedish entity |
0 | -7 074 |
| Net profit/(loss) for the period after technical recycling of CTA Adjustments for: |
24 294 | -1 010 |
| Depreciation and impairment of property, plant and equipment | 1 907 | 2 406 |
| Amortization and impairment of intangible assets | 1 957 | 2 151 |
| Write-off on receivables Changes in fair value of financial assets (gains)/losses |
324 -576 |
156 -92 |
| Changes in provisions | 340 | 7 275 |
| Deferred taxes | -4 544 | -4 409 |
| Share of result of associates and joint ventures accounted for using the equity method | 6 775 | 2 218 |
| (Profit)/loss on disposal of assets held for sale | 0 | 0 |
| Other non cash items - Impact IAS 21.48 Other non cash items |
9 -3 367 |
7 074 9 569 |
| Net cash flow changes before changes in working capital | 27 119 | 25 338 |
| Trade receivables, other receivables, and deferrals | -578 | -13 006 |
| Inventories and contract in progress | -11 348 | 21 574 |
| Trade payables, other payables, and accruals Other short-term assets and liabilities |
8 174 -6 543 |
-12 975 -13 023 |
| Change in working capital | -10 295 | -17 430 |
| Income tax paid/received, net | -3 769 | -2 865 |
| interest expenses | 1 976 | 1 798 |
| interest (income) | -62 | -78 |
| Net cash (used in)/generated from operations | 14 969 |
6 763 |
| Cash flow from investing activities | ||
| Acquisition of property, plant, and equipment | -2 855 | -1 640 |
| Acquisition of intangible assets | -2 099 | -2 293 |
| Disposal of fixed assets Acquisitions of subsidiaries, net of acquired cash |
25 0 |
1 681 0 |
| Acquisition of third party and equity-accounted companies | -1 524 | 0 |
| Disposal of subsidiaries | 2 433 | 13 127 |
| Disposals of other investments and equity-method-accounted companies, net of assigned | 5 738 | 170 |
| cash Other investing cash flows |
2 | -5 190 |
| Net cash (used in)/generated from investing activities | 1 720 | 5 855 |
| Cash flow from financing activities | ||
| Proceeds from borrowings S.R.I.W. Reverse convertible bond |
0 5 000 |
10 024 0 |
| Repayments of borrowings | -15 199 | -34 200 |
| Interest paid | -2 086 | -1 809 |
| Interest received | 62 | 78 |
| Capital increase (or proceeds from issuance of ordinary shares) | 7 845 | 986 |
| Purchase of treasury shares Dividends paid |
0 -140 |
0 0 |
| Other financing cash flows | -3 807 | -3 012 |
| Net cash (used in)/generated from financing activities | -8 325 | -27 933 |
| Net cash and cash equivalents at the beginning of the year | 29 090 | 45 733 |
| Changes in net cash and cash equivalents Exchange gains/(losses) on cash and cash equivalents |
8 364 -278 |
-15 315 -1 328 |
| Net cash and cash equivalents at the end of the year | 37 176 | 29 090 |
IBA sa. | Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | Tel.: + 32 10 47 58 11 | Fax: + 32 10 47 58 10 | E-mail: [email protected] | www.iba-worldwide.com | RPM Nivelles | VAT: BE 0428.750.985
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.